The major areas of effort in this project have been (1) To refine existing methodologies for the study of cortical functioning based on positron emission tomography (PET); (2) To develop new tracers or other approaches for the study of neurotransmitter function in normal and abnormal physiology; (3) To apply what tracer methodologies we have available to the study of neuropsychiatric disorders. To these ends the following achievements are notable. Our study of schizophrenic patients, on and off neuroleptics, receiving repeated somatosensory stimulation (SS) during metabolic measurement in comparison to normals by FDG-PET i.e., the study of regional brain activities through observations of regional glucose metabolic rates (lCMRglu's) as calculated from PET scan meaasurements of 18F-deoxyglucose accumulation has been completed and differences reported. This work provided weak support for the existence of """"""""hypofrontality"""""""" in schizophrenia, and did not find any improvement in hypofrontality when patients were treated. We have completed the collection of data on the study of two additional behavioral paradigms with FDG-PET. These studies were of auditory continuous performance (CPT), and rest (REST) and totaled 43 normals. Altogether the data allowed us to develop a statistical approach to the handling of PET data that is both sensitive to the small changes observed upon behavioral changes while maintaining reliability. It provides evidence that SS may not be a good condition for observing hypofrontality except perhaps within one particular area of the frontal cortex. Most importantly, the data from this comparison strongly supports the heterogenity of the frontal cortex and the need to examine very carefully the detailed pattern of metabolism in the frontal cortex if we are to understand the physiology and pathophysiology of behavior.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Intramural Research (Z01)
Project #
1Z01MH000507-04
Application #
3968452
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1986
Total Cost
Indirect Cost
Name
U.S. National Institute of Mental Health
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Cohen, Robert M; Szczepanik, Joanna; McManus, Michael et al. (2006) Hippocampal atrophy in the healthy is initially linear and independent of age. Neurobiol Aging 27:1385-94
Cannon-Spoor, H Eleanor; Levy, James A; Zubenko, George S et al. (2005) Effects of previous major depressive illness on cognition in Alzheimer disease patients. Am J Geriatr Psychiatry 13:312-8
Toyama, Hiroshi; Ye, Daniel; Ichise, Masanori et al. (2005) PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging 32:593-600
Levy, James A; Bergeson, Judy; Putnam, Karen et al. (2004) Context-specific memory and apolipoprotein E (ApoE) epsilon 4: cognitive evidence from the NIMH prospective study of risk for Alzheimer's disease. J Int Neuropsychol Soc 10:362-70
Sunderland, Trey; Mirza, Nadeem; Putnam, Karen T et al. (2004) Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry 56:670-6
Podruchny, Teresa A; Connolly, Catherine; Bokde, Arun et al. (2003) In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse 48:39-44
Cohen, Robert M; Podruchny, Teresa A; Bokde, Arun L W et al. (2003) Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-epsilon4 allele. Synapse 49:150-6
Doudet, D J; Holden, J E; Jivan, S et al. (2000) In vivo PET studies of the dopamine D2 receptors in rhesus monkeys with long-term MPTP-induced parkinsonism. Synapse 38:105-13
Elkashef, A M; Doudet, D; Bryant, T et al. (2000) 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 100:11-Jan
Wyatt, R J; Henter, I D; Bartko, J J (1999) The long-term effects of placebo in patients with chronic schizophrenia. Biol Psychiatry 46:1092-105

Showing the most recent 10 out of 11 publications